Pathophysiology and medical treatment of pain in fibrous dysplasia of bone - Archive ouverte HAL Access content directly
Journal Articles Orphanet Journal of Rare Diseases Year : 2012

Pathophysiology and medical treatment of pain in fibrous dysplasia of bone

(1, 2) , (1, 2) , (3) , (4) , (5) , (3, 4, 6)
1
2
3
4
5
6

Abstract

One of the most common complications of fibrous dysplasia of bone (FD) is bone pain. Usual pain killers are often of inadequate efficacy to control this bone pain. The mechanism of bone pain in FD remains uncertain, but by analogy with bone tumors one may consider that ectopic sprouting and formation of neuroma-like structures by sensory and sympathetic nerve fibers also occur in the dysplastic skeleton. Bone pain has been reported in up to 81% of adults and 49% of children. It affects predominantly the lower limbs and the spine. The degree of pain is highly variable and adults reports more pain than children. Bisphosphonates have been shown to reduce bone pain in uncontrolled studies. Their influence on bone strength remains unknown. In a randomized trial testing alendronate, bone pain was not significantly improved. Another trial assessing the effect of risedronate is ongoing. Possible future therapies include tocilizumab, denosumab and drugs targeting nerve growth factor and its receptor TrkA.
Fichier principal
Vignette du fichier
1750-1172-7-S1-S3.pdf (311.46 Ko) Télécharger le fichier
Vignette du fichier
1750-1172-7-S1-S3.xml (65.32 Ko) Télécharger le fichier
Origin : Publisher files allowed on an open archive
Format : Other
Loading...

Dates and versions

inserm-00701189 , version 1 (24-05-2012)

Identifiers

  • HAL Id : inserm-00701189 , version 1

Cite

Roland Chapurlat, Deborah Gensburger, Juan Jimenez-Andrade, Joseph Ghilardi, Marilyn Kelly, et al.. Pathophysiology and medical treatment of pain in fibrous dysplasia of bone. Orphanet Journal of Rare Diseases, 2012, 7 (Suppl 1), pp.S3. ⟨inserm-00701189⟩
142 View
407 Download

Share

Gmail Facebook Twitter LinkedIn More